Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.
PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.
Biological: autologous tumor cell vaccine
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx|
|Study Start Date:||December 1971|
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002454
|United States, New Jersey|
|New Jersey Medical School|
|Newark, New Jersey, United States, 07103-2714|
|Study Chair:||James M. Oleske, MD||Rutgers, The State University of New Jersey|